[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"age-related-macular-degeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:age-related-macular-degeneration":162},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,64,0,25,[9,45,72,88,122,191,213,237,249,275,298,327,349,370,392,419,445,471,495,519,540,561,588,610,635],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053345","phase-1-study-to-assess-the-adverse-events-and-how-intravitreal-abbv-6628-moves-through-the-body-of-adult-participants-with-geographic-atrophy-secondary-to-age-related-macular-degeneration-100053345",false,"NCT07160179","Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration","Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of ABBV-6628 in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration","Inclusion Criteria:\n\nStage 1 and Stage 2\n\n-Diagnosed with Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in the study eye.\n\nStage 1\n\n* Foveal or non-foveal GA with total GA lesion area ≥ 0.5 DA (1.25 mm2) in the study eye, as assessed by the investigator at Screening and confirmed by the central reading center prior to Baseline\u002FDay 1\n* Absence of choroidal neovascularization (CNV) in the study eye as assessed by the investigator at Screening and confirmed by the central reading center prior to Baseline\u002FDay 1. In addition, investigators should confirm eligibility prior to treatment administration on Baseline\u002FDay 1.\n\nStage 2\n\n* Non-foveal GA with total lesion area of 1 to 7 DA (2.5 to 17.5 mm2); within 0.5 to 1.5 mm from fovea center in the study eye, as assessed by the investigator at Screening and confirmed by the central reading center prior to Baseline\u002FDay 1.\n* Absence of CNV in both eyes as assessed by the investigator at Screening and confirmed by the central reading center prior to Baseline\u002FDay 1. In addition, investigators should confirm eligibility prior to treatment administration on Baseline\u002FDay 1.\n\nExclusion Criteria:\n\nStage 1 and Stage 2\n\n* History of recurrent or currently active ocular or intraocular inflammation (e.g., uveitis, endophthalmitis) in at least one eye at Screening and Baseline\u002FDay 1.\n* Active periocular, ocular, or intraocular infection in at least one eye at Baseline\u002FDay 1.\n* History or clinical signs of diabetic retinopathy, diabetic macular edema (DME), or any retinal vascular disease other than AMD in at least one eye at Screening and Baseline\u002FDay 1.","ALL","50 Years",{"count":20,"type":21},66,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","Age-related macular degeneration (AMD) is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. Geographic Atrophy (GA) is an advanced form of dry AMD. The purpose of this study is to assess the adverse events and how intravitreal ABBV-6628 moves through the body of adult participants with secondary to age-related macular degeneration\n\nABBV-6628 is an investigational monoclonal antibody fragment being developed for the treatment of geographic atrophy (GA) secondary to (AMD) age-related macular degeneration. Participants in the Stage 1 part will be placed in 1 of 4 groups, called treatment arms. Participants in Stage 2 will be placed into 1 of 2 groups. Each group receives different treatment. Adult participants aged 50 and older years with a diagnosis GA secondary to age-related macular degeneration will be enrolled. Around 66 participants will be enrolled in the study at approximately 27 sites across the US.\n\nParticipants in Stage 1 will be given ABBV-6628 as an intravitreal injection (injection into the jelly-like tissue that fills the eyeball injection) with dose escalation. Participants in Stage 2 will receive ABBV-6628 or SYFOVRE, an approved treatment for geographic atrophy, administered as per the FDA-approved label. The treatment duration is approximately 22 months and 3 months of follow-up.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.",[28,29],"Geographic Atrophy","Age-Related Macular Degeneration",[28,29,31],"ABBV-6628","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2025-08-13",{"date":40,"type":21},"2029-10",{"name":42,"class":43},"AbbVie","INDUSTRY",5,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100631122","phase-2-a-clinical-trial-of-eye201mk-8748-in-people-with-macular-degeneration-mk-8748-003-100631122","NCT07496567","A Clinical Trial of EYE201\u002FMK-8748 in People With Macular Degeneration (MK-8748-003)","A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2\u002F3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201\u002FMK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)","TORRONTES","The main inclusion criteria include but are not limited to the following:\n\n* Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and polypoidal choroidal vascularization (PCV) lesions in at least one eye (study eye)\n* The diagnosis of neovascular age-related macular degeneration (NVAMD) must have been made within 21 days prior to starting study treatment\n\nThe main exclusion criteria include but are not limited to the following\n\n* Has uncontrolled blood pressure at screening\n* History of any prior macular laser photocoagulation in the study eye\n* History of uveitis in either eye\n* History of cataract surgery, minimally invasive glaucoma surgery, or Yttrium-Aluminium Garnet (Yag) laser capsulotomy in the study eye within 90 days before entering the study\n* Has uncontrolled glaucoma in the study eye\n* Active retinal disease other than the condition under investigation in the study eye\n* Has previously received anti- vascular endothelial growth factor (VEGF) therapy or other intravitreal (IVT) therapy in the study eye",{"count":54,"type":21},960,[25,56],"PHASE3","Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).\n\nAvailable standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD.\n\nThe goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.",[59,29,60,61],"Macular Degeneration","Choroidal Neovascularization","Wet Macular Degeneration","2026-06-27",{"date":64,"type":36},"2026-06-30",{"date":66,"type":36},"2026-04-15",{"date":68,"type":21},"2028-07-31",{"name":70,"class":43},"EyeBiotech Ltd.",48,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":50,"acronym":77,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":57,"conditions":80,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100626791","phase-2-a-clinical-trial-of-eye201mk-8748-in-people-with-macular-degeneration-mk-8748-002-100626791","NCT07440225","A Clinical Trial of EYE201\u002FMK-8748 in People With Macular Degeneration (MK-8748-002)","MALBEC",{"count":54,"type":21},[25,56],[59,29,60,61],{"date":64,"type":36},{"date":83,"type":36},"2026-03-27",{"date":85,"type":21},"2028-06-30",{"name":70,"class":43},71,{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":95,"sex":17,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":101,"conditions":102,"keywords":107,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":4,"leadSponsor":118,"locationsCount":121},"100170772","national-eye-institute-biorepository-for-retinal-diseases-100170772","NCT01496625","National Eye Institute Biorepository for Retinal Diseases","NEI Intramural Biorepository for Retinal Diseases","* INCLUSION CRITERIA:\n\nParticipants will be eligible if they:\n\n* Have the ability to understand and sign an informed consent or have a parent\u002Flegal guardian to do so if they are minor children.\n* Manifest diagnosed or undiagnosed retinal disease(s), or could serve as an unaffected control suitable for comparison to participants with various retinal diseases, particularly AMD and diabetic retinopathy (taking into account matching factors such as age and past ocular history).\n\nEXCLUSION CRITERIA:\n\nParticipants will not be eligible if they:\n\n* Are unable or unwilling to give informed consent that includes collection and study of at least one peripheral blood sample.\n* Are unable or unwilling to give informed consent that includes use of NIH medical records and clinical samples for research.\n* Have a systemic disease that compromises the ability to provide adequate ophthalmologic examination or treatment.",true,"2 Years","120 Years",{"count":99,"type":21},650,"OBSERVATIONAL","Background:\n\n\\- To understand diseases of the retina and the eye, information is needed about people with and without such diseases. Researchers want to study these people and follow them over time. They also want to study body tissues and blood to understand the nature of eye disease. Studying genes, cells, and tissues may help them understand why some people get eye problems and others do not, or why some people respond to treatment while others do not. Researchers want to collect physical samples and personal data to develop a National Eye Institute database.\n\nObjectives:\n\n\\- To collect health information and blood and tissue samples from people with and without eye diseases, to be used in research studies.\n\nEligibility:\n\n* Individuals at least 2 years of age with different types of eye disease.\n* Healthy volunteers with no history of eye disease.\n\nDesign:\n\n* Participants may be recruited from National Eye Institute studies or may be referred from other sources.\n* Participants will be screened with a physical exam and medical history. They will also have a full eye exam. Questions will be asked about family medical history, especially about eye disease.\n* Blood samples will be collected. Other samples, such as saliva, tears, hair, stool, and urine, may be collected as needed. Adult participants may also provide a skin sample.\n* Tissue or fluid from eye collected as part of eye care or treatment may also be added to the database.\n* No treatment will be provided as part of this study.",[29,103,104,105,106],"Diabetic Retinopathy","Von Hippel-Lindau Syndrome","Retinal Disease","Retinal Vein Occlusion",[108,105,103,109,110,111,112,113,114],"Biological Specimens","Phenotype-Genotype correlation","Age-Related Macular Degeneration (AMD)","Natural History","AMD","Healthy Volunteer","HV",{"date":64,"type":36},{"date":117,"type":36},"2012-06-18",{"name":119,"class":120},"National Eye Institute (NEI)","NIH",1,{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":12,"sex":17,"minAge":130,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":135,"conditions":136,"keywords":152,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":188,"locationsCount":190},"100286660","stem-cell-ophthalmology-treatment-study-ii-100286660","NCT03011541","Stem Cell Ophthalmology Treatment Study II","Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II","SCOTS2","Inclusion Criteria:\n\n* Have objective, documented damage to the retina or optic nerve unlikely to improve OR\n* Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20\u002F30 best corrected central visual acuity in one or both eyes AND\u002FOR an abnormal visual field in one or both eyes.\n* Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.\n* If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).\n* Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n* Be over the age of 18\n* Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure.\n* Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n* Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology.\n* Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol.\n* Patients who are not capable of providing informed consent.\n* Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure.","18 Years",{"count":132,"type":21},500,[134],"NA","This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.",[105,29,137,138,139,140,141,142,143,144,145,146,147,148,149,150,59,151],"Retinitis Pigmentosa","Stargardt Disease","Optic Neuropathy","Nonarteritic Ischemic Optic Neuropathy","Optic Atrophy","Optic Nerve Disease","Glaucoma","Leber Hereditary Optic Neuropathy","Blindness","Vision Loss Night","Vision Loss Partial","Vision, Low","Retinopathy","Maculopathy","Retina Atrophy",[153,154,155,156,157,158,159,160,161,105,59,162,163,28,164,61,165,166,167,168,137,138,169,170,171,150,142,141,139,172,173,174,175,176,177,178,179,180,144,145,181,151],"Stem Cells","Bone Marrow Derived Stem Cells","BMSC","Mesenchymal Stem Cells","MSC","Eye Disease","Ophthalmology","Ophthalmic Disease","Retina","Age Related Macular Degeneration","Myopic Macular Degeneration","Dry Macular Degeneration","Retinal Atrophy","Retinal Dystrophy","Hereditary Retinal Dystrophy","Malattia Leventinese","Cone Dystrophy","Rod-Cone Dystrophy","Cone-Rod Dystrophy","Ischemic Optic Neuropathy","Optic Nerve Damage","Optic Nerve Compression","Compressive Optic Neuropathy","Devics Syndrome","Ushers Syndrome","Neuromyelitis Optica","Dominant Optic Atrophy","Kjers Optic Atrophy","Vision Loss","2026-06-24",{"date":184,"type":36},"2026-06-29",{"date":186,"type":36},"2016-01",{"date":68,"type":21},{"name":189,"class":43},"MD Stem Cells",4,{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":17,"minAge":130,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":121},"100536938","multicenter-real-life-observational-study-switched-aflibercept-or-ranibizumab-to-faricimab-in-patients-with-amd-100536938","NCT06271330","Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.","A Multicenter Real-life Observational Retrospective Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With Refractory or Dependent Exudative AMD","FAR-WEST","Inclusion Criteria:\n\n* Male or female patient of legal age (≥18 years) with exudative AMD treated with IVT ranibizumab or aflibercept \\> 1 year.\n* Patient whose IVT injection interval is strictly less than 12 weeks.\n\nExclusion Criteria:\n\n* Severe myopia (axial length \\> 26 mm or sphere \\\u003C - 6 dioptres).\n\n  * Presence of angioid striae.\n  * Presence of moderate or more severe diabetic retinopathy.\n  * History of diabetic macular edema.\n  * History of uveitis.\n  * Previous retinal vein occlusion (branch or central vein).\n  * History of pseudovitelliform macular dystrophy.\n  * Patient under guardianship or trusteeship\n  * Pregnant or breast-feeding woman",{"count":200,"type":21},100,"Age-related macular degeneration (AMD) is a degenerative retinal disease. The prognosis of the exudative form was transformed by the introduction of the anti-VEGF monoclonal antibody treatments ranibizumab \\[1\\] and aflibercept \\[2\\] in the 2010s. In 2022, a new molecule, Faricimab, proved its efficacy in exudative AMD. It is a bi-specific monoclonal antibody against VEGF-A and ANG2. The drug has been granted marketing authorization in France, with reimbursement due to begin in October 2023 for naïve patients as well as for those already treated with ranibizumab or aflibercept. The main advantage of this compound \\[3\\] is that it extends the injection interval in the Treat and Extend (T\\&E) protocol, which is more extensive than with previous anti-VEGF agents.\n\nThe patients included in the faricimab Phase III study were all naïve to any anti-VEGF treatment. In practice, faricimab is likely to offer hope to patients already treated with anti-VEGF with a short injection interval to lengthen the number of weeks between injections.\n\nAs the treatment will be on sale in pharmacies from October 2023, a switch study from previous anti-VEGF drugs to faricimab would contribute to an initial real-life evaluation of the drug in this indication.",[203],"Age-related Macular Degeneration","2026-06-23",{"date":182,"type":36},{"date":207,"type":36},"2024-04-01",{"date":209,"type":21},"2026-09",{"name":211,"class":212},"Nantes University Hospital","OTHER",{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":221,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":236},"100641097","predicting-risk-of-progression-of-early-to-late-amd-in-the-aging-eye-through-imaging-and-multimodal-evaluation-100641097","NCT07653269","Predicting Risk of Progression of Early to Late AMD in the Aging Eye Through Imaging and Multimodal Evaluation","Predicting Risk of Progression of Early to Late AMD in the Aging Eye Through Imaging and Multimodal Evaluation - PRIME Study","PRIME","Inclusion Criteria:\n\n* Adults aged 55 years or older\n* No severe systemic illnesses that prevent study participation\n* Willing and able to undergo protocol-required procedures for both eyes\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Systemic disorders that preclude reliable clinical examination or multimodal imaging\n* Poor compliance or severe mental illness that hinders participation\n* Persons who are unable to give informed consent","55 Years",{"count":223,"type":21},1500,"The purpose of this research study is to evaluate a new screening procedure for the early detection and monitoring of Age-related Macular Degeneration (AMD) in community settings and community hospital settings, to identify associated risk factors, and develop personalized monitoring strategies for at-risk individuals throughout the 5 years follow up period, which will allow us to establish prevalence, natural history of progression of early AMD in the community.",[162],"2026-06-17",{"date":228,"type":36},"2026-06-18",{"date":230,"type":36},"2025-10-18",{"date":232,"type":21},"2029-07-31",{"name":234,"class":235},"Singapore National Eye Centre","OTHER_GOV",2,{"id":238,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":26,"conditions":241,"keywords":242,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":247,"leadSponsor":248,"locationsCount":190},"100605258",{"count":20,"type":21},[24,25],[28,29],[28,29,31],"2026-06-11",{"date":245,"type":36},"2026-06-15",{"date":38,"type":36},{"date":40,"type":21},{"name":42,"class":43},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":17,"minAge":130,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":22,"phases":258,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":121},"100642827","phase-1-phase-1-study-of-c001-in-retinal-degeneration-100642827","NCT07594236","Phase 1 Study of C.001 in Retinal Degeneration","A Phase I Single-Center Open-label Study of C.001 in Patients With Significant Retinal Pigment Epithelium Mediated Maculopathy (RMM)","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of retinal disease associated with retinal pigment epithelium degeneration (e.g., geographic atrophy or Stargardt disease)\n* Visual acuity within protocol-defined limits\n* Stable ocular condition prior to enrollment\n* Medically suitable for ophthalmic surgery and anesthesia\n* Willingness to comply with study procedures and follow-up\n\nExclusion Criteria:\n\n* Active or prior choroidal neovascularization (CNV)\n* Recent myocardial infarction or significant uncontrolled cardiovascular disease\n* Uncontrolled glaucoma\n* Significant ocular inflammatory disease\n* Recent intraocular surgery within protocol-defined timeframe\n* Active systemic infection\n* Poorly controlled diabetes (e.g., HbA1c \\>8.5%)\n* Participation in another investigational study within 3 months prior to screening",{"count":257,"type":21},15,[24],"This is a first-in-human Phase 1 study evaluating the safety and tolerability of C.001 in patients with retinal diseases involving degeneration of the retinal pigment epithelium.\n\nParticipants will receive a single administration of C.001 delivered by subretinal injection. The study will evaluate three dose levels in a sequential manner.\n\nThe primary objective is to assess the safety of C.001 over a 3-month period following administration. Participants will be followed for up to 12 months to further evaluate safety and explore changes in visual function and retinal structure.",[28,138,261,162],"RPE-mediated Maculopathy",[263,264,265],"macular degeneration","macular distrophy","C.001","2026-06-10",{"date":268,"type":36},"2026-06-12",{"date":270,"type":36},"2026-04-07",{"date":272,"type":21},"2029-12-31",{"name":274,"class":43},"Cellio Therapeutics Inc",{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":95,"sex":17,"minAge":283,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":121},"100343530","village-integrated-eye-worker-trial-ii-100343530","NCT03752840","Village-Integrated Eye Worker Trial II","Village-Integrated Eye Worker Trial II (VIEW II):A Cluster-randomized Trial of the Effectiveness of Community-based Ocular Disease Screening","VIEW II","Community level\n\nInclusion Criteria:\n\n* Located in catchment area of Bharatpur Eye Hospital or Lumbini Eye Institute\n* Reachable by non-4WD vehicle\n* Urban or peri-urban\n\nExclusion Criteria:\n\n\\- Local leaders unwilling to participate\n\nPerson level\n\nInclusion Criteria:\n\n* 60 years and older\n* Residing in the community during the time of the census\n\nExclusion Criteria:\n\n\\- Unwilling to participate","60 Years",{"count":285,"type":21},60200,[134],"The vast majority of blindness is avoidable. The World Health Organization (WHO) estimates that 80% of cases of visual impairment could be prevented or reversed with early diagnosis and treatment. The leading causes of visual impairment are cataract and refractive error, followed by glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy (DR). Loss of vision from these conditions is not inevitable; however, identifying cases early and linking cases with appropriate care remain significant challenges.\n\nTo address the global burden of avoidable blindness, eye care systems must determine optimal strategies for identifying people with or predisposed to visual impairment beyond opportunistic screening. Outreach programs can prevent blindness both by screening for asymptomatic disease like age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma and case detection of symptomatic disease like cataract and refractive error. Eye care systems have developed numerous approaches to these identification methods, including screening using telemedicine and case detection via cataract camps or health worker models, but no studies have been conducted on the comparative effectiveness or cost effectiveness of these various approaches.\n\nTechnology promises to greatly improve access to sophisticated eye care. AMD, DR, and glaucoma can result in irreversible vision loss, and early diagnosis and effective treatment can prevent progression. Thus, mass screening programs may prevent progression and improve the vision of a population. However, mass screening for eye disease is currently not recommended. Although self-evident that early detection can prevent blindness for an individual, no randomized controlled trial has been able to demonstrate that screening improves visual acuity at the regional level. However, recent technological advances promise to dramatically change the equation by allowing non-medical personnel to use mobile, easy-to-use retinal imaging devices to diagnose screenable eye diseases such as AMD, DR, and glaucoma. Mobile technology could also transform the way clinics communicate with their patients, improving linkage to and retention in care.\n\nOptical coherence tomography (OCT) is an ideal test for screening. OCT can be performed through an undilated pupil and is less subject to optical aberrations due to cataract than is fundus photography. OCT machines have pre-installed algorithms to screen for glaucoma, and major anatomical abnormalities can easily be detected even by novice technicians. The infrared image allows detection of referable diabetic retinopathy, and newer OCT angiography machines offer even more discrimination of early diabetic retinopathy. OCT machines are ever more portable, and could be feasibly used in mobile screening programs.\n\nThe investigators propose a large cluster-randomized trial to compare two population level blindness prevention programs: (1) a state-of-the-art screening program employing OCT, fundus photography, and intraocular pressure testing to screen for glaucoma, DR, and AMD followed by enhanced linkage-to-care to the local eye hospital, and (2) a screening program involving only visual acuity assessment. An initial door-to-door census will assess baseline visual acuity in both study arms. The investigators will compare visual acuity between the two arms through a second door-to-door census 9 years later (primary outcome).",[203,103,143],"2026-06-05",{"date":291,"type":36},"2026-06-09",{"date":293,"type":36},"2019-04-21",{"date":295,"type":21},"2029-08-31",{"name":297,"class":212},"University of California, San Francisco",{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":22,"phases":307,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":317,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":4},"100639516","phase-2-phase-2a-study-to-evaluate-the-efficacy-and-safety-of-scai-005-ophthalmic-solution-in-subjects-with-neovascular-age-related-macular-degeneration-100639516","NCT07607561","Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration","A Randomization, Double-blind, Placebo-controlled, Parallel, Multicenter, Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration","Inclusion Criteria:\n\n1. Adults aged 50 years or older\n2. Subjects who were diagnosed with nAMD in the study eye within 3 years prior to the Screening Visit, who demonstrated a treatment response to at least 3 repeated intravitreal injections of anti-VEGF IVT for nAMD, and whose last anti-VEGF IVT administration was more than 12 weeks prior to the planned date of the first administration of the investigational product.\n3. Active MNV secondary to nAMD with a subfoveal component related to the MNV activity in the study eye as assessed by FA (evidence of leakage) or SD-OCT (presence of fluid) at screening\n4. CST ≤ 450 μm at screening\n5. BCVA ETDRS letter score of 80 letters to 25 letters in the study eye as measured by the ETDRS visual acuity chart at screening\n\nExclusion Criteria:\n\n1. Subjects with choroidal neovascularization in the study eye due to causes other than nAMD (however, polypoidal choroidal vasculopathy (PCV) can be enrolled)\n2. Presence of scarring, fibrosis, or atrophy involving the fovea in the study eye at Screening\n3. Subjects who have a hemorrhage in the subfoveal region of the study eye and in whom the subretinal hemorrhage area is ≥ 1 optic disk area\n4. History of glaucoma surgery, vitrectomy, submacular surgery, or macular laser treatment (e.g., photodynamic therapy \\[PDT\\], laser photocoagulation, etc.) in the study eye\n5. Subjects with vitreous hemorrhage in the study eye\n6. History of ocular treatment (except for anti-VEGF IVT therapy), systemic treatment, or surgical intervention for the treatment of neovascular age-related macular degeneration (nAMD) in the study eye\n7. Administration of intraocular, periocular, or intravitreal (IVT) steroid injection in the study eye within 24 weeks prior to Screening\n8. Presence of diabetic retinopathy, diabetic macular edema, or other vascular diseases affecting the retina, other than neovascular age-related macular degeneration (nAMD), in either eye\n9. History of endophthalmitis or idiopathic or autoimmune-related uveitis in either eye\n10. Subjects with active macular neovascularization identified in the fellow eye at Screening",{"count":306,"type":21},50,[25],"Trial to Evaluate the Safety and Efficacy of SCAI-005 Ophthalmic solution in Patients with Neovascular Age-related Macular Degeneration.\n\nThe purpose of this study is to investigate the efficacy, safety and tolerability of SCAI-005 Ophthalmic solution by dose in patients with neovascular Age-related Macular Degeneration (nAMD).",[310,162],"wetAMD",[310,312,313,314,315,316],"CNV","eyedrop","TKI","Axitinib","Phase2","NOT_YET_RECRUITING","2026-05-20",{"date":320,"type":36},"2026-05-26",{"date":322,"type":21},"2026-11-01",{"date":324,"type":21},"2027-08-31",{"name":326,"class":43},"SCAI Therapeutics",{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":95,"sex":17,"minAge":221,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":22,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":317,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":121},"100639742","feasibility-study-of-a-remote-behavioral-dietary-intervention-in-patients-with-early-to-intermediate-amd-glucose-lowering-for-vision-extension-100639742","NCT07605468","Feasibility Study of a Remote Behavioral Dietary Intervention in Patients With Early to Intermediate AMD: Glucose Lowering for Vision Extension","Nonrandomized, Unmasked Feasibility Study of a Remote-based Behavioral Dietary Intervention in Patients With Early to Intermediate AMD: Glucose Lowering for Vision Extension (GLOVE)","GLOVE","Inclusion Criteria:\n\n* Diagnosis of early to intermediate AMD with no history of retinal geographic atrophy (cRORA) or exudative disease\n* Eating a diet less healthy than average (Healthy Eating Index \\[HEI\\] score \\\u003C61) based on 3 24-hour dietary recalls\n* Access to a computer or smart phone for use in the behavioral meetings (we will provide loaners for those lacking a smart phone\n* Because the initial questionnaires (ASA24), surveys and informed consent will be on line and in English, only individuals with fluency in English will be included. (They do not need to list English as their primary language.)\n\nExclusion Criteria:\n\n* HbA1c greater than 6.5%,\n* Diabetes or medications used to treat diabetes or obesity (including GLP1 agonists, metformin, glyburide\n* Use of statins, niacin or other lipid\u002Fcholesterol modifying medications\n* Recent cancer (within past 3 years)\n* Other retinal or ocular pathology (other than pseudophakia and\u002For refractive error (between -8 to +8 diopter spherical equivalence)","75 Years",{"count":337,"type":21},32,[134],"The primary goal of the study is to test dietary intervention at glycemic control and carotenoid levels in participants with intermediate age-related macular degeneration.",[29],"2026-05-18",{"date":320,"type":36},{"date":344,"type":21},"2026-06",{"date":346,"type":21},"2028-06",{"name":348,"class":212},"Stanford University",{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":22,"phases":358,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":236},"100501017","phase-1-safety-of-bbc1501-intravitreal-injection-in-patients-with-neovascular-age-related-macular-degeneration-namd-100501017","NCT05803785","Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)","A Phase 1, Open Label, Ascending Dose Study to Evaluate the Safety of BBC1501 Administered by Intravitreal Injection for Neovascular Age-Related Macular Degeneration (nAMD)","Key Inclusion Criteria:\n\n* Able to provide voluntary written informed consent on the approved ICF, understand the study requirements, and are willing to follow and complete all the study required procedures.\n* Male or female aged ≥ 50 years.\n* As per the Investigator's judgment, patients with active CNV lesions (ie, foveal or parafoveal) secondary to nAMD, as confirmed with SD-OCT, FFA, and fundus photography (FP) in the study eye. Patients must have received at least two prior anti-VEGF doses (eg, aflibercept, ranibizumab, bevacizumab, brolicizumab, or faricimab), meeting criteria for non-ideal response\n* Active CNV lesions, secondary to nAMD as confirmed with SD-OCT (or SS-OCT), FFA and fundus photography (FP) in the study eye.\n* BCVA score of between 73 and 21 letters, inclusive, in the study eye using ETDRS testing (Snellen equivalent score between 20\u002F40 and 20\u002F400, inclusive\n* Participant has CST \\> 250 μm if measured by Cirrus OCT or \\> 270 μm if measured by Spectralis OCT, with presence of intraretinal and\u002For subretinal fluid\n* Participants who have had a washout period of at least six weeks prior to first administration of the IMP for any IVT anti-VEGF medication and, who in the opinion of the investigator, have disease sufficiently stable to enable this interval.\n\nKey Exclusion Criteria:\n\n* Use of any of the following treatments or anticipated use of any of the following treatments to the study eye:\n* Intravitreal or periocular corticosteroid, within 90 days prior to Visit 1 (Day 1) and throughout the study.\n* Glaucoma, evidenced by an IOP of \\> 21 mmHg despite up to 4 glaucoma medications, or evidence of glaucomatous visual field loss or has advanced glaucoma (e.g., prior shunt surgery) in either eye\n* Evidence of any other ocular disease other than nAMD in the study eye that may confound the outcome of the study (eg, active diabetic retinopathy, posterior uveitis, pseudovitelliform macular degeneration, moderate\u002Fsevere myopia).\n* Participants with advanced nAMD and no prognosis of BCVA as per Investigator's judgement (e.g. due to macular OCT signs of atrophy or photoreceptors disruption, or macular\u002Ffoveal subretinal hemorrhage).\n* Need for ocular surgery in the study eye during the course of the study.\n* YAG laser capsulotomy within 30 days prior to Visit 1 in the study eye.\n* Intraocular surgery, including lens removal or laser, within 90 days prior to Visit 1 in the study eye.\n* Ocular or periocular infection in either eye.\n* Pupillary dilation inadequate for quality stereoscopic fundus photography in the study eye.\n* Media opacity that would limit clinical visualization, intravenous fluorescein angiography, or spectral-domain optical coherence tomography (SD-OCT) evaluation in the study eye.\n* History of herpetic infection in the study eye or adnexa.\n* Presence of known active toxoplasmosis, inactive toxoplasmosis or toxoplasmosis scar in either eye.\n* Presence of any form of ocular malignancy including choroidal melanoma in either eye",{"count":357,"type":21},18,[24],"This open-label study is being conducted to evaluate the initial safety and tolerability of BBC1501 IVT in patients with nAMD. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of IVT BBC1501 in patients with nAMD. The secondary objective of this study is to exploratory of BBC1501 efficacy following 3 ascending dose of BBC1501 in nAMD patient.",[29],"2026-05-13",{"date":363,"type":36},"2026-05-15",{"date":365,"type":36},"2025-07-01",{"date":367,"type":21},"2026-12",{"name":369,"class":43},"Benobio Co., Ltd.",{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":95,"sex":17,"minAge":18,"maxAge":377,"enrollmentInfo":378,"targetDuration":4,"studyType":22,"phases":379,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":121},"100561687","early-phase-1-the-role-of-occupational-therapy-for-improving-medication-management-for-persons-with-amd-dr-and-glaucoma-100561687","NCT06593405","The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma","The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, Diabetic Retinopathy (DR) and Glaucoma","Inclusion Criteria:\n\n* Clients with AMD, DR or Glaucoma\n* Clients who choose to participate will allow their deidentified data to be evaluated for outcomes.\n\nExclusion Criteria:\n\n* Clients with other age related eye diseases other than AMD, DR or Glaucoma.\n* Clients who do not wish to participate in this study.","100 Years",{"count":306,"type":21},[380],"EARLY_PHASE1","The goal of this clinical trial is to learn if education about additional task lighting, enhanced contrast, enlarged print instructions, smart apps and organizational strategies will improve medication management skills. The main questions it aims to answer are:\n\nDoes additional task lighting, enhanced contrast, enlarged print instructions, smart apps and organizational strategies improve medication management skills, reduce errors and improve functional use of remaining vision for this task?\n\nParticipants will:\n\nOftentimes, the client is unaware of these strategies which may improve occupational performance during a valued activity. Clients with AMD, DR or Glaucoma who choose to receive the one hour OT service will be provided with 1:1 education regarding the devices and strategies that may improve their ability to perform medication management skills.",[29],"2026-05-11",{"date":385,"type":36},"2026-05-12",{"date":387,"type":36},"2025-04-22",{"date":389,"type":21},"2026-12-05",{"name":391,"class":212},"MCPHS University",{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":17,"minAge":398,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":236},"100466567","adaptive-optics-imaging-of-outer-retinal-diseases-100466567","NCT05355415","Adaptive Optics Imaging of Outer Retinal Diseases","Inclusion Criteria:\n\n1. Are 21 years of age or older,\n2. Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam),\n3. Have the ability to understand and sign an informed consent. (Non-English speaking participants will not be enrolled into the study), and\n4. Have been diagnosed with outer retinal disease or condition (Cohort 2).\n\nExclusion Criteria:\n\n1. Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity),\n2. Have visual correction outside of the range +4 diopters (D) to -8 D,\n3. Have a history of adverse reaction to mydriatic drops,\n4. Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG), or\n5. Are working under the direct supervision of Drs. Hammer, Cukras and Liu, or any of the NIH\u002FNEI AIs.","21 Years",{"count":200,"type":21},"The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.",[402,29,137,403,404,405,169,406,407,408],"Retinal Degeneration","Hydroxychloroquine Retinopathy","Usher Syndromes","Late-Onset Retinal Degeneration","Cone Rod Dystrophy","Rod Cone Dystrophy","Rod Dystrophy","2026-05-06",{"date":411,"type":36},"2026-05-08",{"date":413,"type":36},"2021-08-27",{"date":415,"type":21},"2028-09-30",{"name":417,"class":418},"Food and Drug Administration (FDA)","FED",{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":17,"minAge":283,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":22,"phases":428,"briefSummary":429,"conditions":430,"keywords":434,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":442,"locationsCount":444},"100566975","microcurrent-stimulation-therapy-for-intermediate-to-advanced-nonexudative-age-related-macular-degeneration-100566975","NCT06662162","Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration","Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration (i-SIGHT2): a Multicentre, Randomised, Sham-controlled, Double-masked, Clinical Device Trial.","i-SIGHT2","Key Inclusion Criteria:\n\n* Presence of at least one large druse \\>125 microns in diameter due to AMD.\n* BCVA letter score of 35 to 70 letters (inclusive) (Snellen equivalent 6\u002F12 to 6\u002F60 \\[20\u002F40 to 20\u002F200\\])\n\nKey Exclusion Criteria:\n\n* Any implanted electrical device(s) including deep brain stimulator, hearing or visual implants (i.e., cochlear implant, auditory brainstem implant, retinal prostheses), and\u002For cardiac defibrillator\u002Fpacemaker.\n* Implanted metallic device within 20 cm of the Treatment electrode (study eye(s)) and\u002For the grounding electrode (base of the hairline on the back of the neck).\n* Uncontrolled diabetes, defined as glycated haemoglobin (HbA1c) \\>10% (13.3 mmol\u002FL).\n* Current tobacco or tobacco-related product use or history within the past 5 years of heavy smoking (defined as, on average, more than half a pack of cigarettes per day).\n* Known severe allergy to fluorescein dye.\n* Medical diagnosis of severe dry eye defined as requiring either artificial tears more than six (6) times a day or prescription drops (i.e., Restasis, Xiidra, or Cequa).\n* History of seizure disorders, chronic migraines and\u002For cluster headaches.\n* History and\u002For evidence of diabetic retinopathy in either eye as assessed by CF, fundus fluorescein angiography (FA), and OCT, to be confirmed by the Central Reading Centre.\n* Other conditions which pre-dispose to chorioretinal atrophy such as inherited retinal dystrophy (i.e., Stargardt's disease, Best's disease, pattern dystrophy, central areolar choroidal dystrophy, etc.).\n* History and\u002For evidence of exudative AMD in the study eye as assessed by CF, FA (or OCT-A ), and OCT, to be confirmed by Central Reading Centre.\n* GA involving the foveal centre, as assessed by the Central Reading Centre using AF and OCT.\n* History of intravitreal injections for GA (e.g., Syfovre or Izervay).\n* Treatment with photobiomodulation (PBM) therapy or short pulse laser within 12 months prior to screening.\n* Glaucoma requiring ≥3 medications and\u002For drops per day, or history of trabeculectomy.\n* History of any kind of intraocular surgery, excluding cataract surgery performed ≥3 months from Screening.\n* History of yttrium aluminium garnet (YAG) laser posterior capsulotomy \\\u003C1 month from Screening.\n* Visually significant cataracts and\u002For visually significant posterior capsular opacification.\n* History of amblyopia.",{"count":200,"type":21},[134],"The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.\n\nParticipants will:\n\n* Undergo an initial loading regimen, followed by 7 maintenance over the course of 11 months.\n* Participants will return monthly through Month 14 (3 months post-last treatment) for evaluation and monitoring.",[29,431,432,433],"Age-related Macular Degeneration (ARMD)","Intermediate AMD","Geographic Atrophy Secondary to Age-related Macular Degeneration",[112,432,435,28],"Dry AMD","2026-05-01",{"date":438,"type":36},"2026-05-04",{"date":440,"type":36},"2025-05-07",{"date":272,"type":21},{"name":443,"class":43},"i-Lumen Scientific AUS PTY LTD",13,{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":95,"sex":17,"minAge":452,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":455,"conditions":456,"keywords":459,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":121},"100198971","high-resolution-retinal-imaging-100198971","NCT01866371","High Resolution Retinal Imaging","AOSLO","Inclusion Criteria:\n\n* Males or females age 7 years or older.\n* Parental\u002Fguardian permission (informed consent) and if appropriate, child assent. Child subjects age 7-17 must give assent.\n* Reasonable compliance with an imaging protocol as determined by the study personnel.\n\nExclusion Criteria:\n\n* Individuals that are at risk to acute glaucoma.\n* Individuals that are photophobic and experience adverse psychological reactions to flashes of light.\n* Ocular opacities, high refractive error, and high frequency of nystagmus as determined by the study team.","7 Years",{"count":454,"type":21},600,"Studying the morphology and function of the normal and diseased retina in vivo is needed for advancing the detection, diagnosis, and treatment of retinal disease. This protocol uses an adaptive optics scanning laser ophthalmoscope (AOSLO) to image the normal and diseased retina with individual cellular resolution non-invasively. The primary objective of this study is to obtain and analyze high-resolution images of the retina, in particular by imaging the cone photoreceptor mosaic, the retinal vasculature and other retinal layers. The study design will involve case-control studies, where cases are followed over time. Subjects age 7 and older may be invited to participate. The main research procedure involves retinal imaging with the AOSLO. The primary endpoint is the observation of differences in retinal images between subjects with and without retinal diseases. These changes will be quantified by examining the cell density, size, spacing and regularity of the cone photoreceptor mosaic, as well as examining the differences between other retinal layers.",[457,137,203,458,28],"Stargardts","Choroideremia",[161,460,461],"imaging","retinal degeneration","2026-04-28",{"date":464,"type":36},"2026-05-05",{"date":466,"type":4},"2013-05",{"date":468,"type":21},"2031-12",{"name":470,"class":212},"University of Pennsylvania",{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":17,"minAge":283,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":22,"phases":480,"briefSummary":481,"conditions":482,"keywords":483,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":494,"locationsCount":121},"100588607","strategies-for-improving-linkage-to-care-after-eye-disease-screening-100588607","NCT06943599","Strategies for Improving Linkage-to-Care After Eye Disease Screening","Village Integrated Eye Worker II Linkage-to-Care Trial","Inclusion Criteria:\n\n\\- Participant of the VIEW II study referred to the eye hospital at their eye screening visit.\n\nExclusion Criteria:\n\n* Residence in an area without reliable mobile connectivity",{"count":479,"type":21},3000,[134],"The goal of this randomized, parallel-group, controlled trial is to compare methods of improving linkage-to-care for participants in the Village Integrated Eye Worker II (VIEW II) trial who are referred to the eye hospital following eye disease screening. Participants who are referred to the hospital at an eye screening visit will be randomized to three different linkage-to-care interventions: (1) text message reminders, (2) reminders from health workers, or (3) no intervention. The primary outcome of the trial will be whether or not the participant presented to the eye hospital for a referral visit by 21 days following screening.",[162,103,143],[484,485,486,487],"Eye Diseases","mass screening","patient compliance","retention in care","2026-04-27",{"date":490,"type":36},"2026-04-29",{"date":492,"type":36},"2026-02-01",{"date":85,"type":21},{"name":297,"class":212},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":95,"sex":17,"minAge":503,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":22,"phases":506,"briefSummary":507,"conditions":508,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":236},"100594099","developing-and-testing-a-model-to-identify-preventive-vision-loss-among-older-patients-in-general-practice-100594099","NCT07015034","Developing and Testing a Model to Identify Preventive Vision Loss Among Older Patients in General Practice","Developing and Testing a Model to Identify Preventive Vision Loss Among Older Patients in General Practice (DETECT)","DETECT","Inclusion Criteria:\n\n* +70 years\n* One or more chronic diseases\n* Are followed by GP du to chronic disease\n\nExclusion Criteria:\n\n* Dementia diagnosis\n* Known eye-diseases or are currently followed by private ophtalmologist\n* Not able to understand Danish","70 Years",{"count":505,"type":21},460,[134],"In this cohort study, the investigators will test vision screenings in Danish general practice for patients over 70 years of age with minimum one chronic condition. The main outcome is detection of vision impairment and secondary outcome is detection of conditions needing ophthalmologic follow-up but not presenting vision impairment at present time.",[509,143,29,510,103],"Vision Impairment and Blindness","Cataract","2026-04-23",{"date":490,"type":36},{"date":514,"type":36},"2024-05-15",{"date":516,"type":21},"2027-07-15",{"name":518,"class":212},"University of Copenhagen",{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":17,"minAge":221,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":528,"conditions":529,"keywords":530,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":121},"100635724","central-microperimetry-and-radial-oct-evaluation-in-geographic-atrophy-core-ga-a-prospective-pilot-study-100635724","NCT07556406","Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study","CORE-GA","Inclusion Criteria:\n\n* Subjects must be 55+ years of age Subjects in the \"Intermediate AMD Observation Arm\" must have intermediate age-related macular degeneration in one eye\n\nSubjects in the \"GA Observation Arm\", \"GA Continuing Treatment Arm\", and \"GA Treatment Arm\" must have non-central GA (defined as GA has not involved the center point of the fovea) and at least 1% GA in the central 1 mm zone.\n\nExclusion Criteria:\n\n* Subjects with central involvement of GA. Central involvement is defined as geographic atrophy involving the foveal center point.\n\nSubjects with a baseline size of GA \\> 17.5mm2 (7.0 Macular Photocoagulation Study Disc Areas).\n\nSubjects who are: pregnant women, adults who cannot consent for themselves, and those who use alcohol in excess. Excess alcohol use is defined by binge drinking (pattern of drinking that brings blood alcohol concentration levels to 0.08 g\u002FdL) on 5 or more days in the past month.\n\nEvidence of retinal atrophy due to causes other than atrophic AMD. Subjects who have had anti-VEGF injections or active choroidal neovascularization in the study eye during the last 12 months Current evidence or history of ocular disorders in the study eye that in the opinion of the investigator confounds study outcome measures, including (but not limited to):\n\n1. Non-proliferative diabetic retinopathy involving 10 or more hemorrhages or microaneurysms, or active proliferative diabetic retinopathy\n2. Branch or central retinal vein or artery occlusion\n3. Macular hole\n4. Pathologic myopia\n5. Uveitis\n6. Pseudovitelliform maculopathy\n7. Intraoperative surgery within the last 90 days prior to study eye enrollment",{"count":527,"type":21},80,"This study is being conducted to assess two imaging methods-central microperimetry and radial OCT (Optical Coherence Tomography)-in patients with Geographic Atrophy (GA) or those who are at risk of developing this condition. The study team is trying to determine whether these methods can provide more accurate measurements of GA progression toward the foveal center, the central part of the retina responsible for your sharpest, most detailed vision.",[29,28],[531,532],"age-related macular degeneration","geographic atrophy","2026-04-22",{"date":490,"type":36},{"date":536,"type":36},"2025-06-11",{"date":538,"type":21},"2027-06-11",{"name":297,"class":212},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":95,"sex":17,"minAge":130,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":22,"phases":548,"briefSummary":549,"conditions":550,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":121},"100635660","defining-retinal-structures-using-hyperspectral-retinal-imaging-100635660","NCT07555574","Defining Retinal Structures Using Hyperspectral Retinal Imaging","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Able to provide informed consent\n* Willing and able to attend a study visit at the Centre for Eye Research Australia\n* Participants with diagnosed retinal or optic nerve disease (e.g., diabetic retinopathy, glaucoma, age-related macular degeneration)\n* Age- and sex-matched healthy control participants without known retinal or optic nerve disease\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Ocular conditions preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous haemorrhage)\n* Known contraindication to pharmacological pupil dilation\n* History of narrow anterior chamber angle or risk of angle closure glaucoma where dilation is considered unsafe\n* Any condition that, in the investigator's opinion, would compromise participant safety or image quality",{"count":547,"type":21},1000,[134],"This study evaluates hyperspectral retinal imaging as a novel, non-invasive imaging technique to characterise retinal and optic nerve structures in healthy individuals and patients with eye disease. Hyperspectral imaging captures retinal data across multiple wavelengths to generate detailed spectral information that may reveal features not visible with conventional retinal photography.\n\nApproximately 1000 participants will undergo multi-modal ophthalmic imaging in Melbourne, Australia, including hyperspectral imaging, OCT, fundus photography, and related tests. The study aims to compare hyperspectral imaging with standard imaging methods and assess its ability to identify retinal biomarkers associated with diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration.",[29,103,143,551,552],"Retinal Diseases","Healthy Volunteers","2026-04-21",{"date":490,"type":36},{"date":556,"type":36},"2025-01-01",{"date":558,"type":21},"2028-12-30",{"name":560,"class":212},"Center for Eye Research Australia",{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":95,"sex":17,"minAge":568,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":22,"phases":571,"briefSummary":572,"conditions":573,"keywords":574,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":121},"100350888","visual-remapping-to-aid-reading-with-field-loss-100350888","NCT03848663","Visual Remapping to Aid Reading With Field Loss","Remapping the Visual Field to Aid Reading With Central Scotomas","Inclusion Criteria:\n\n1. 16 years or older\n2. Central vision loss of at least 5 deg diameter, including the fovea, from bilateral central scotomas\n3. Stable fixation (+\u002F- 1 deg) using their PRL.\n4. No cognitive impairment as indicated by a Mini-Mental State Examination (MMSE).\n5. Satisfactory calibration achievable using eye tracker\n\nExclusion Criteria:\n\n1. Central vision loss of less than 5 deg diameter; scotomas that do not cover the fovea; unilateral scotomas\n2. Poor fixation (worse than+\u002F- 1 deg) using their PRL.\n3. Cognitive impairment as indicated by a Mini-Mental State Examination (MMSE).\n4. Satisfactory calibration not achievable using eye tracker","16 Years",{"count":570,"type":21},108,[134],"Reading performance in patients with Central Vision Loss and age matched controls with artificial scotomas will be measured with and without different kinds of remapping of missing text to different parts of the visual field.",[203],[575,576,577,578,579],"Scotoma","Remapping","Reading","Low vision","Visual aid","2026-04-16",{"date":533,"type":36},{"date":583,"type":36},"2022-02-01",{"date":585,"type":21},"2026-07-01",{"name":587,"class":212},"University of Minnesota",{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":95,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":594,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":595,"conditions":596,"keywords":597,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":609},"100587102","age-related-macular-degeneration-benchmark-imaging-dataset-abid-100587102","NCT06924021","Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)","Inclusion Criteria:\n\n* Participants greater than or equal to 50 years of age at time of signing Informed Consent Form\n* Willing to comply with all study procedures and sign the Informed Consent Form (ICF)\n* Individuals with normal healthy eyes or diagnosed with any stage of Age-Related Macular Degeneration (treatment naïve patients with early, intermediate, or late AMD). The diagnosis and eligibility review will be confirmed by Central Reading Center.\n\nExclusion Criteria:\n\n* Therapeutic treatment for any type of AMD, in either eye. Supplements, such as AREDS2 formula, are allowed.\n* Unable to acquire adequate quality images, as evaluated by the Central Reading Center\n* Severe vision loss requiring urgent surgery\n* Contraindicated for acquiring retinal images due to narrow anterior chamber angles or hypersensitivity to light\n* A systemic or ocular condition that in the opinion of the Investigator would preclude participation in the study\n* Unwilling to sign informed consent form\n* Currently or previously enrolled in an interventional AMD clinical trial",{"count":547,"type":21},"1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.",[29],[598,599,600],"screening","artificial intelligence","AI","2026-03-25",{"date":83,"type":36},{"date":604,"type":36},"2025-05-12",{"date":606,"type":21},"2026-11",{"name":608,"class":212},"University of Wisconsin, Madison",14,{"id":611,"slug":612,"hasResults":12,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":4,"eligibilityCriteria":616,"healthyVolunteers":95,"sex":17,"minAge":130,"maxAge":4,"enrollmentInfo":617,"targetDuration":4,"studyType":22,"phases":618,"briefSummary":619,"conditions":620,"keywords":621,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":121},"100509410","direct-discrimination-of-quantum-states-by-the-human-eye-100509410","NCT05913063","Direct Discrimination of Quantum States by the Human Eye","Direct Discrimination of Quantum States by the Human Eye With Macular Degeneration","Inclusion Criteria:\n\n* Participants who are clinically diagnosed with a vision disease affecting their macula\n* Older adults who are matched for age.\n* Participants who are clinically diagnosed with glaucoma\n* Participants who have normal vision.\n* One aged-matched control with normal vision will be recruited for each of the diagnosed groups (born in the same year).\n\nExclusion Criteria:\n\n* Participants with any additional eye diagnosis or condition",{"count":306,"type":21},[134],"Age-related macular degeneration (AMD), is a debilitating eye disease that causes a loss of central vision. The prevalence of AMD increases exponentially with age and causes a significant impact through both medical expenses and the social and economic costs associated with vision loss. AMD is the global leading cause of blindness among people over the age of 60. Detection of this eye disease at early stages coupled with prompt treatment can prevent vision loss; however, modern diagnosis methods are ineffective at diagnosis of AMD before vision loss occurs. While a range of available treatment options has been effective at slowing vision loss due to AMD, no treatment exists which can recover lost vision. The investigators propose to apply tools developed in quantum information science to diagnose AMD before vision has been affected, drastically improving health outcomes for patients with AMD.",[29],[29,622,623,624,625],"Structured Light","Orbital Angular Momentum","Polarization Perception","Retinal Imaging","2026-03-16",{"date":628,"type":36},"2026-03-18",{"date":630,"type":36},"2023-06-26",{"date":632,"type":21},"2029-10-01",{"name":634,"class":212},"Centre for Eye and Vision Research",{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":4,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":642,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":644,"conditions":645,"keywords":646,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":121},"100512942","progression-of-early-atrophic-lesions-100512942","NCT05959005","Progression of Early Atrophic Lesions","Progression of Early Atrophic Lesions in Age-related Macular Degeneration (AMD).","Inclusion Criteria:\n\n* Males and females aged 50 years and older of all ethnicities.\n* Study eye with at least one early atrophic lesion defined as:\n* incomplete retinal pigment epithelium (RPE) and outer retinal atrophy (iRORA) (region of signal hypertransmission into the choroid, corresponding zone of attenuation or disruption of the RPE, and evidence of overlying photoreceptor degeneration that is, subsidence of the inner nuclear layer (INL) and outer plexiform layer (OPL), presence of a hyporeflective wedge in the Henle fiber layer (HFL), thinning of the outer nuclear layer (ONL), disruption of the external limiting membrane (ELM), or disintegrity of the ellipsoid zone (EZ), or\n* complete RPE and outer retinal atrophy (cRORA) (homogeneous choroidal hypertransmission, absence of the RPE band measuring \\> 250µm, evidence of overlying photoreceptor degeneration) and total lesions size =\\\u003C ½ disc area (DA) (corresponding to 1.27mm2 area) of all atrophic lesions measured on fundus-autofluorescence (FAF) imaging in the study eye.\n* Sufficiently clear ocular media, adequate pupillary dilatation, and adequate fixation to permit quality fundus imaging and unbiased functional testing incl. fundus-controlled perimetry (FCP) testing.\n* Ability to comply with study protocol timelines.\n\nExclusion Criteria:\n\n* Signs or exudation defined as serous detachment of the sensory retina, intraretinal cystoid fluid, or subretinal\u002Fretinal hemorrhage in the study eye.\n* cRORA lesion \\>1\u002F2 disc area in the study eye at baseline.\n* Any history of treatment of exudative macular neovascularization (MNV) in the study eye (e.g. type 1, type 2, mixed, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation); Note: Non-exudative type 1 MNV in the study eye is NOT an exclusion criterion; non-exudative or exudative MNV in the fellow eye is not an exclusion criterion. Fellow-eyes may receive treatment of exudative MNV as part of clinical care.\n* Any disease\u002Fdisorder other than AMD in the study eye at the time of inclusion (e.g. monogenic retinal diseases, diabetic retinopathy, retinal detachment, previous retinal surgeries, myopic degeneration), uncontrolled glaucoma with intraocular pressure (IOP) of \\>30 mmHg (despite current pharmacological or non-pharmacological treatment) and uveitis.\n* History of central retinal laser treatment, including photodynamic therapy (PDT) and subthreshold laser treatment for AMD in the study eye.\n* Cataract surgery in the study eye within the last three months prior to enrollment. Laser-capsulotomy in the study eye within the last 2 weeks prior to enrollment.\n* Current or previous participation in clinical trials investigating drugs or supplements in AMD (except vitamins and minerals).\n* Current or previous participation (\\\u003C3 months from termination of participation) in clinical trials investigating drugs or supplements in diseases other than AMD.\n* Any concurrent ocular condition in the study eye (e.g. cataracts) that, in the opinion of the investigator, requires medical or surgical intervention during the study period to prevent or treat visual loss that might result from that condition or - if allowed to progress untreated - could likely contribute to loss of at least two Snellen equivalent lines of best-corrected visual acuity during the study period.\n* Concomitant diseases that in the opinion of the investigator would make adherence to the examination schedule difficult or unlikely (e.g. personality disorder, chronic alcoholism, Alzheimer's Disease, drug abuse).\n* Evidence of significantly uncontrolled concomitant diseases at the discretion of the investigator (e.g. cardiovascular, neurological, pulmonary, renal, hepatic, endocrine gastrointestinal disorder).",{"count":643,"type":21},125,"Early atrophic age-related macular degeneration (AMD) represents an important time window in the course of so far untreatable atrophic AMD, as patients typically experience only some degree of visual dysfunction, while being at significant risk for marked further loss of vision. To allow the precise evaluation of upcoming therapeutic interventions, a better understanding of the manifestation and variable disease progression is needed. This project aims to investigate refined tools to detect and monitor early atrophic AMD more accurately, including the impact on visual dysfunction and quality of life.",[29],[647,648,28,649],"iRORA","cRORA","non-exudative","2026-03-08",{"date":652,"type":36},"2026-03-11",{"date":654,"type":36},"2023-10-20",{"date":656,"type":21},"2028-12-31",{"name":658,"class":212},"University of Utah"]